NOVEL AGENT THAT INHIBITS ANGIOGENESIS AND METASTASIS TARGETING mTOR SIGNALING PATHWAY
AssigneesJe-Ho Lee, Kyoungsook Park
InventorsJe-Ho LEE, Kyoungsook Park, Kyusam Choi
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel function of Msx1 protein for inhibiting tumor angiogenesis and metastasis by targeting mTOR (mammalian target of rapamycin) signaling pathway, and for treating a cancer in a subject. Particularly, Msx1 suppresses mTOR through a direct interaction with mTOR, resulting in the inhibition of angiogenesis. The Msx1 significantly suppresses tumor angiogenesis that is necessary for the growth, invasion, and metastasis of solid tumors. Ad-Msx1 can be used to effectively inhibit tumor metastasis by suppressing angiogenesis, tumor cell invasion, and migration.
Claims14
A method of inhibiting angiogenesis of a tumor in subject, comprising administering to the subject a therapeutically effective amount of Msx1 protein consisting of an amino acid sequence of SEQ ID NO:1.
A method of treating a cancer in a subject, comprising administering to the individual an effective amount of a therapeutically effective amount of Msx1 protein consisting of an amino acid sequence of SEQ ID NO:1.
Dependencies are inferred from the claim text.